Lupin Limited (Lupin) announced the launch of first generic version of Oracea® (Doxycycline Capsules, 40 mg), in the United States, after having received an approval from the United States Food and Drug Administration (U.S. FDA). Doxy cycline Capsules, 40 mg is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. Doxycycline Capsules had estimated annual sales of USD 128 million in the U.S. (IQVIA MAT February 2024).
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,632 INR | +0.15% | +3.01% | +23.32% |
Jun. 05 | Lupin Arm Acquires Two Brands from Sanofi in Europe and Canada | MT |
May. 30 | India's pharma export sales to grow faster this year, trade body says | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.32% | 8.89B | |
+45.82% | 765B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.85% | 248B | |
-1.39% | 219B | |
+11.04% | 216B | |
+5.90% | 164B | |
-0.73% | 162B |
- Stock Market
- Equities
- LUPIN Stock
- News Lupin Limited
- Lupin Limited Announces the Launch of First Generic Version of Oracea® (Doxycycline Capsules, 40 Mg), in the United States